The socioeconomics of diabetes from a developing country: A population based cost of illness study

Tharkar, Shabana; Devarajan, Arutselvi; Kumpatla, Satyavani; Viswanathan, Vijay

doi:10.1016/j.diabres.2010.05.009

Cited by 130 publications

(120 citation statements)

References 15 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…The indirect cost of DM per capita per mo estimated by Tharkar was INR 415 [8], closely resembling our study, whereas Bahia et al have reported a higher cost of INR 4278 [9]. The high cost reported by Bahia could be due to the inclusion of patients with complicated DM and hospitalization for assessment of COI.…”

Section: Discussioncontrasting

confidence: 38%

Burden of Therapy in Patients Suffering From Diabetes Mellitus and Hypertension

Ramanna

Ruckmani

Janti

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: To estimate a) monthly expenditure for treatment of diabetes mellitus (DM), hypertension (HTN) and both (DM+HTN) and b) economic burden (EB) and psychological burden (PB) of therapy of DM, HTN and DM+HTN.Methods: An observational questionnaire-based study was conducted among 180 patients. The monthly cost of drug therapy was assessed based on the drugs they were taking and the cost of individual drugs. The EB and PB were assessed using a validated questionnaire and data analysed by ANOVA followed by post hoc test.Results: Among 216 patients who were interviewed, 180 fulfilled the selection criteria. Among 180, 75 had DM, 40 HTN and 65 had both. Prevalence of DM and DM+HTN was higher among females and of HTN equal among males and females. The average total monthly cost of therapy for DM was INR 2077, for HTN INR 1464 and for DM+HTN INR 2269.Significant correlation was found between income and percentage of expenditure (p<0.001) in all the groups. The PB was found to correlate with low income (p<0.001), poor education (p<0.05) occupation (p<0.01) in DM+HTN and number of tablets (p<0.01) in DM and DM+HTN groups. Conclusion:The cost of therapy was higher for DM+HTN and DM. The percentage of expenditure was higher in low-income group and burden of therapy was directly proportional to the number of tablets, poor educational and occupational status; and inversely proportional to income.

show abstract

Section: Discussioncontrasting

confidence: 38%

Burden of Therapy in Patients Suffering From Diabetes Mellitus and Hypertension

Ramanna

Ruckmani

Janti

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…It is a growing health problem in most countries and its incidence is considered to be high (4%-5%) all over the world [1] . Chronic hyperglycemia causes complications linked to diabetes, such as heart disease, retinopathy, kidney disease, and neuropathy.…”

Section: Introductionmentioning

confidence: 99%

Hypoglycemic effect of Brassica juncea (seeds) on streptozotocin induced diabetic male albino rat

Thirumalai

Therasa

Elumalai

et al. 2011

Asian Pacific Journal of Tropical Biomedicine

View full text Add to dashboard Cite

“…A problem for funders and policymakers is that, in diabetes care, costs have to be incurred upfront to gain savings decades later. An Indian study, for example, found that 60% of people had to use personal savings for their diabetes care, while only 2% of people on high incomes had insurance coverage for diabetes 42 . In these circumstances, our finding that starting insulin detemir was cost-effective according to GDP criteria even over 1 year is potentially helpful: an early investment delivering an early healthcare gain.…”

Section: Discussionmentioning

confidence: 99%

An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

Home

Baik

Gálvez

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

Aims:There is limited evidence with respect to the cost-effectiveness of starting insulin in people with diabetes outside the 'western' world. The aim of this study was to assess the cost-effectiveness of starting basal insulin treatment with insulin detemir in people with type 2 diabetes (T2D) inadequately controlled on oral glucose-lowering drugs (OGLDs) in Mexico, South Korea, India, Indonesia, and Algeria. Methods:The IMS CORE Diabetes Model was used to project clinical and cost outcomes over a 30-year time horizon. Clinical outcomes, baseline characteristics and health state utility data were taken from the A 1 chieve study. A 1-year analysis was also conducted based on treatment costs and quality-of-life data. Incremental costeffectiveness ratios (ICERs) were expressed as a fraction of GDP per capita, and WHO-CHOICE recommendations (ICER53.0) used to define cost-effectiveness. Results:Starting insulin detemir was associated with a projected increase in life expectancy (!1 year) and was considered cost-effective in all of the studied populations with ICERs of À0.02 (Mexico), 0.00 (South Korea), 0.48 (India), 0.12 (Indonesia), and 0.88 (Algeria) GDP/quality-adjusted life-year. Cost-effectiveness was maintained after conducting sensitivity analyses in the 30-year and 1-year analyses. A projected increase in treatment costs was partially offset by a reduction in complications. The difference in overall costs between insulin detemir and OGLDs alone was USD518, 1431, 3510, 15, and 5219, respectively. Conclusion:Changes in clinical outcomes associated with starting insulin detemir in insulin-naïve individuals with T2D resulted in health gains that made the intervention cost-effective in five countries with distinct healthcare resources.

show abstract

The socioeconomics of diabetes from a developing country: A population based cost of illness study

Cited by 130 publications

References 15 publications

Burden of Therapy in Patients Suffering From Diabetes Mellitus and Hypertension

Burden of Therapy in Patients Suffering From Diabetes Mellitus and Hypertension

Hypoglycemic effect of Brassica juncea (seeds) on streptozotocin induced diabetic male albino rat

An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

Contact Info

Product

Resources

About